234 related articles for article (PubMed ID: 28449867)
1. Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Athanasakis K; Boubouchairopoulou N; Tarantilis F; Tsiantou V; Kontodimas S; Kyriopoulos J
Clin Ther; 2017 May; 39(5):993-1002. PubMed ID: 28449867
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
3. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility of first-line actinic keratosis treatments in Finland.
Soini EJ; Hallinen T; Sokka AL; Saarinen K
Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
[TBL] [Abstract][Full Text] [Related]
5. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
Colombo GL; Chimenti S; Di Matteo S; Fargnoli MC; Frascione P; Silipo V; Peris K
G Ital Dermatol Venereol; 2010 Oct; 145(5):573-81. PubMed ID: 20930692
[TBL] [Abstract][Full Text] [Related]
7. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.
Wilson EC
Pharmacoeconomics; 2010; 28(11):1055-64. PubMed ID: 20936887
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients.
Norrlid H; Norlin JM; Holmstrup H; Malmberg I; Sartorius K; Thormann H; Jemec GBE; Ragnarson Tennvall G
J Dermatolog Treat; 2018 Feb; 29(1):68-73. PubMed ID: 28658998
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States.
Asche CV; Zografos P; Norlin JM; Urbanek B; Mamay C; Makin C; Erntoft S; Chen CC; Hines DM; Mark Siegel D
Value Health; 2016; 19(2):239-48. PubMed ID: 27021759
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life.
Diepgen TL; Eicke C; Bastian M
Eur J Dermatol; 2019 Aug; 29(4):401-408. PubMed ID: 31625920
[TBL] [Abstract][Full Text] [Related]
12. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT).
Kim YC; Yang JY; Yoon JS; Jo SJ; Ahn HH; Song KH; Lee DY; Chung KY; Won YH; Kim IH
Br J Dermatol; 2018 Oct; 179(4):836-843. PubMed ID: 29355904
[TBL] [Abstract][Full Text] [Related]
14. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
[TBL] [Abstract][Full Text] [Related]
16. Daylight methyl-aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment of actinic keratoses: an intraindividual comparative analysis.
Genovese G; Fai D; Fai C; Mavilia L; Mercuri SR
Dermatol Ther; 2016 May; 29(3):191-6. PubMed ID: 26799440
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
18. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
Nisticò S; Torchia V; Gliozzi M; Bottoni U; Del Duca E; Muscoli C
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):796-804. PubMed ID: 27207444
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
